celecoxib and tramadol, marketed under the brand name Seglentis, received FDA approval on October 15, 2021.

Maralixibat, marketed under the brand name Livmarli, received FDA approval on September 29, 2021.

atogepant is FDA approved. Atogepant, marketed under the brand name Qulipta, received FDA approval on September 28, 2021.

Tisotumab vedotin (Tivdak) received accelerated approval from the US Food and Drug Administration (FDA) on September 20, 2021.

Mobocertinib (Exkivity) received accelerated approval from the US Food and Drug Administration (FDA) on September 15, 2021.

Lonapegsomatropin (Skytrofa) received FDA approval on August 25, 2021.

The U.S. Food and Drug Administration (FDA) approved Difelikefalin on August 23, 2021, for the treatment of moderate-to-severe pruritus (itching) associated with chronic kidney disease in adults undergoing hemodialysis (HD).

The U.S. Food and Drug Administration (FDA) approved Belzutifan on August 13, 2021, for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC).

The U.S. Food and Drug Administration (FDA) approved Avalglucosidase alfa for the treatment of late-onset Pompe disease (LOPD) on August 6, 2021.

The U.S. Food and Drug Administration (FDA) approved Anifrolumab for the treatment of moderate to severe systemic lupus erythematosus (SLE) in adults on July 30, 2021.

The U.S. Food and Drug Administration (FDA) approved Twyneo for use in the treatment of acne vulgaris on July 26, 2021.

The U.S. Food and Drug Administration (FDA) approved belumosudil on July 16, 2021.